lilly glp-1 drugs Study flags need to monitor frailty risks with for older adults America has a new weight-loss
Description
Risk of bias: all four RCTs were rated low risk by RoB2 (with some concerns for open-label outcome ascertainment in three trials, a domain-specific issue that does not alter the overall RoB2 category from low)
This is where wellness starts to collide with pharma
Supports overall daily wellness
This is the first study to investigate the unique underlying mechanisms related the effects of GLP-1RA on changes in the gut bacterium.
This review summarizes comparative evidence for providers who are determining which of the two classes may be the most appropriate for a specific patient
